PR
Therapeutic Areas
Afrigen Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| COVAX-19 | COVID-19 | Phase 2 |
| AfriMab-1 | HER2‑positive breast cancer | Preclinical |
| AfriMab-2 | Solid tumors (PD‑1 inhibition) | Preclinical |
| Biosimilar Rituximab | Autoimmune diseases | Preclinical |
| Biosimilar Trastuzumab | HER2‑positive cancers | Preclinical |